Delos Capital and AP Biosciences Inc. Launch Strategic Partnership to Develop Next-Generation Antibody-Based Therapies

• The partnership unites venture creation and biologics discovery to expedite the development of novel medicines up to human clinical proof of concept
• This marks a first-of-its-kind collaboration between a specialized biotech venture firm and a publicly-traded biopharmaceutical company
• Initial focus is on autoimmune diseases, utilizing bi- and tri-specific antibody approaches that integrate innovative and de-risked targets and mechanisms

(SeaPRwire) –   CAMBRIDGE, Mass. and TAIPEI, Taiwan, May 11, 2026 — Delos Capital (“Delos”) and AP Biosciences, Inc. (“APBio”), today announced a strategic collaboration to establish and nurture new biotechnology companies. The initial emphasis is on the discovery and advancement of novel immune-related drug candidates through early clinical proof of concept.

This model draws on Delos’ proven experience in forming and guiding biotech enterprises, combined with APBio’s fully integrated R&D capabilities and operational efficiency across Greater China, facilitating faster and more capital-efficient translation from groundbreaking concepts to clinical-stage assets.

Under this collaboration, Delos, through its Delos Foundry, will oversee therapeutic ideation, financing, and strategic development. APBio, which has experience advancing molecules from discovery through pivotal Phase 3 clinical studies, will contribute its proprietary antibody discovery platform and translational expertise.

“Building and leading biotech companies defines our team’s core identity at Delos, which is why we are advancing our Delos Foundry,” said Henry Chen, founder and managing partner of Delos. “When we do not encounter existing companies aligned with one of our investment theses, our team can bridge that gap by incubating innovative assets under a US-based NewCo. We are pleased to partner with a biologics design firm like APBio, which brings the perspective of a biopharma with full-stack R&D experience.”

Jeng Her, Ph.D., founder and Chief Executive Officer of APBio, added: “This collaboration enables us to amplify the impact of our antibody discovery platforms beyond our internal pipeline. By combining our biologics design capabilities with Delos’ company-building expertise, we can help transform innovative therapeutic concepts into clinically validated programs via a capital-efficient and scalable framework.”

About Delos Capital 
Delos Capital is a life sciences investment firm dedicated to empowering life sciences leaders to convert bold ideas into medical breakthroughs for patients. Our team leverages diverse skills honed as operators and investors at leading biotech organizations, with extensive networks spanning the most significant biotech innovation hubs. Our rigorous investment process integrates a deep understanding of biology, proprietary AI workflows, unmet medical needs, and building high-performing companies to deliver medical breakthroughs to patients. For further information on Delos Foundry, visit www.deloscapital.com/foundry.

About AP Biosciences
AP Biosciences is a clinical-stage biopharmaceutical company based in Taiwan, committed to developing innovative antibody-based therapies for cancer and other diseases. Leveraging its proprietary Omni-Mab and T-Cube platforms, APBio is pioneering next-generation bispecific antibodies designed to enable precise, tumor-targeted immune activation. The company’s pipeline includes multiple clinical-stage programs, as well as partnered assets progressing through later stages of development. For further details, visit www.apbioinc.com.

AP Biosciences Investor Contact
Spike Lo
AP Biosciences
pr@apbioinc.com

AP Biosciences Media Contact
Mike Tattory
LifeSci Communications
mtattory@lifescicomms.com

Delos Capital Contact
info@deloscapital.com